Evidence map›Paper›PMID 39061354›Full record

ArticleAntibiotics (Basel, Switzerland)2024

Structure-Activity Relationship of Pyrrolidine Pentamine Derivatives as Inhibitors of the Aminoglycoside 6'-

Jan Sklenicka, Tung Tran, Maria S Ramirez, Haley M Donow, Angel J Magaña, Travis LaVoi, Yasir Mamun, Verónica Jimenez, Prem Chapagain, Radleigh Santos and 3 more

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Jan SklenickaCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
Tung TranCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
Maria S RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-9904-7890
Haley M DonowCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
Angel J MagañaCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.
Travis LaVoiCenter for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
Yasir MamunDepartment of Physics, Florida International University, Miami, FL 33199, USA.
Verónica JimenezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-0744-8137
Prem ChapagainDepartment of Physics, Florida International University, Miami, FL 33199, USA.ORCID 0000-0002-0999-4975
Radleigh SantosDepartment of Mathematics, Nova Southeastern University, Fort Lauderdale, FL 33314, USA.
Clemencia PinillaDepartment of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
Marc A GiulianottiDepartment of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, Fullerton, CA 92831, USA.ORCID 0000-0002-6298-7811

Funding

DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851k
NIAID NIH HHS R15 AI047115NIGMS NIH HHS SC3 GM125556NIH HHS 2R15AI047115
6 · The paper itself

Abstract

Resistance to amikacin and other major aminoglycosides is commonly due to enzymatic acetylation by the aminoglycoside 6'-

Indexed as

acetyltransferaseAcinetobacteraminoglycoside-modifying enzymesaminoglycoside resistancesmall molecule inhibitorstructure–activity relationship

Identifiers

PMID39061354
PMCPMC11274322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.